Lexicon Pharmaceuticals Inc. (LXRX) had a rough trading day for Friday November 22 as shares tumbled 5.41%, or a loss of $-0.22 per share, to close at $3.85. After opening the day at $4.07, shares of Lexicon Pharmaceuticals Inc. traded as high as $4.15 and as low as $3.75. Volume was 1.36 million shares over 7,222 trades, against an average daily volume of n/a shares and a total float of 106.27 million.
As a result of the decline, Lexicon Pharmaceuticals Inc. now has a market cap of $409.15 million. In the last year, shares of Lexicon Pharmaceuticals Inc. have traded between a range of $8.40 and $1.13, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.
Lexicon Pharmaceuticals Inc. is based out of The Woodlands, TX and has some 202 employees. Its CEO is Lonnel Coats.
Lexicon Pharmaceuticals Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
